Skip to main content
AEON
NYSE Life Sciences

Daewoong Exercises Pre-Funded Warrants, Stake Rises to 30.6% of AEON

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Healthcare
Sentiment info
Neutral
Importance info
7
Price
$0.172
Mkt Cap
$10.163M
52W Low
$0.127
52W High
$1.45
52W Position info
35% above low
Off High info
88% below high
Rel. Volume
Market data snapshot near publication time

AEON sits 35% above its 52-week low of $0.127.

Summary

Daewoong exercised its pre-funded warrants in full on a cashless basis, adding 11.2 million AEON shares and lifting its combined stake to about 30.6% of the 76.0 million shares now outstanding.


Key Events · Ownership and Investor Activity · AEON

  • Daewoong Exercises Pre-Funded Warrants

    On October 30, 2026, Daewoong Pharmaceutical exercised pre-funded warrants for 11,236,631 shares at $0.0001 on a cashless basis; 3,822 shares were withheld at a $0.294 reference price and 11,232,809 shares were issued.

  • Stake Climbs Back to 30.6%

    Combined holdings rose from 12,009,737 to 23,242,546 shares, or about 30.6% of the 76,009,476 shares outstanding as of November 9, 2026, up from roughly 20.3% before the exercise.

  • No Cash to the Company

    The exercise was cashless and no funds were used by the reporting persons, so AEON received no proceeds; the effect is a larger outstanding share count rather than new capital.

  • Remaining Warrants and Note Outstanding

    DWP still holds a warrant for 8,000,000 shares at a $1.09392 strike, subject to a 49.99% ownership blocker, and a Senior Secured Convertible Note convertible only upon a Qualified Financing.


Analysis · AEON · Life Sciences

AEON's largest holder converted its remaining pre-funded warrants for 11.2 million shares at a nominal $0.0001 exercise price, taking Daewoong's combined stake from about 20.3% back to 30.6%. No new cash came in — the warrants were already paid for and the exercise was cashless — so this is a share-count event, not a capital raise. The practical effect is that roughly 11.2 million previously contingent shares are now outstanding and freely held, adding to the tradable float of a stock trading at $0.172. Daewoong remains a controlling-scale holder with an 8 million-share warrant at a $1.09392 strike and a convertible note that only converts on a Qualified Financing, so its influence over AEON is unchanged and its economic exposure is now fully reflected in the share count.

How filings like this one have moved

In the 30 days to Nov 10, 2026, 36.4% of the 3168 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, AEON was trading at $0.17 on NYSE in the Life Sciences sector, with a market capitalization of approximately $10.2M. The 52-week trading range was $0.13 to $1.45. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

AEON - Latest Insights

AEON
Nov 03, 2026, 8:43 AM EST
Filing Type: 424B3
Importance Score:
7
Price at Filing: $0.2797
Real-time Price: $0.172 info
Change: -$0.1077 (-39%) info
Market Cap: $10.163M info
AEON
Nov 03, 2026, 8:42 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.2797
Real-time Price: $0.172 info
Change: -$0.1077 (-39%) info
Market Cap: $10.163M info